DIRS.INFO The most relevant business & tech news

☆ U.S. CDC director experiences COVID rebound after taking Pfizer's Paxlovid
▼ + stars: | 2022-10-31 | by ( ) www.reuters.com time to read: +1 min

Oct 31 (Reuters) - The director of the U.S. Centers for Disease Control and Prevention (CDC), Rochelle Walensky, experienced a COVID-19 rebound after completing a course of Pfizer Inc's (PFE.N) COVID-19 pill, the agency said on Monday. Walensky had experienced mild COVID-19 symptoms less than ten days ago. After completing a course of Pfizer's Paxlovid, and a period of isolation, she had tested negative for the virus, but on Sunday, she tested positive again, CDC added. Some people who took the antiviral drug have suffered from a relapse or a rebound that occurred days after the five-day treatment course had ended, studies have shown. Last month, the U.S. Food and Drug Administration asked Pfizer to test the effects of an additional course of its antiviral Paxlovid among people who had experienced a rebound in COVID-19 after treatment.

☆ The Fed may have to blow up the economy to get inflation under control
▼ + stars: | 2022-10-30 | by ( Paul R. La Monica | ) edition.cnn.com time to read: +7 min

Jobs report also on tapThe Fed meeting takes place just two days before the nation will get its next report card on the labor market. Another jobs report, from payroll processor ADP, is also due out next week, and this one looks just at Corporate America. The government said in the September jobs report that average hourly earnings rose 5% in the past 12 months. The Fed typically prefers to see wage growth in the 2% to 3% annual range as a sign that inflation is under control. Discovery, Starbucks (SBUX), PayPal (PYPL), Amgen (AMGN) and Block (SQ)Friday: US jobs report; earnings from Cardinal Health (CAH), Duke Energy (DUK) and Hershey (HSY)

☆ EU regulator recommends adding heavy periods to side effects of mRNA COVID shots
▼ + stars: | 2022-10-28 | by ( Natalie Grover | ) www.reuters.com time to read: +2 min

[1/2] A medical worker holds a vial of the "Comirnaty" Pfizer-BioNTech COVID-19 vaccine at a coronavirus disease (COVID-19) vaccination center in Nice, France, December 1, 2021. REUTERS/Eric Gaillard/File PhotoOct 28 (Reuters) - A European Medicines Agency (EMA) committee on Friday recommended adding heavy menstrual bleeding to the list of side effect of mRNA COVID-19 vaccines made by Moderna (MRNA.O), as well as Pfizer (PFE.N) and its partner BioNTech (22UAy.DE). The regulator has now concluded that there is at least a "reasonable possibility" that heavy menstrual bleeding is causally associated with these vaccines. Menstrual disorders can occur due to a range of reasons, including underlying medical conditions as well as stress and tiredness. Health authorities have highlighted that cases have also been reported following COVID-19 infection.

☆ Top U.S. official urges caution with RSV, vaccine in development
▼ + stars: | 2022-10-28 | by ( ) www.reuters.com time to read: +2 min

WASHINGTON, Oct 28 (Reuters) - U.S. officials are working on a respiratory syncytial virus (RSV) vaccine, but until one is available people should exercise caution, especially seniors and parents of young children, the nation's top infectious disease official said. A vaccine for the infectious respiratory disease will hopefully come within the next year or two, National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci told MSNBC in an interview. RSV is not a new virus but it is a leading cause of pneumonia in toddlers and the elderly and can lead to hospitalization or death. While there is a higher concentration of RSV impacting U.S. children at the moment, it can also be a serious disease for older adults, he added. "If you're an elderly person, you are vulnerable to the serious consequences of RSV," Fauci told MSNBC.

☆ U.S. government to test Pfizer's Paxlovid for long COVID
▼ + stars: | 2022-10-27 | by ( Julie Steenhuysen | ) www.reuters.com time to read: +2 min

According to details of the study, posted on Clinicaltrials.gov, the randomized, placebo-controlled trial will test Pfizer's treatment or a placebo in 1,700 volunteers aged 18 and older. The trial will investigate a leading theory of the cause of long COVID, which holds that fragments of the virus persist in the tissues of some individuals, causing prolonged symptoms. Patients in several case studies have reported improvements in their symptoms after taking Pfizer's antiviral treatment, and several physicians have called for the drug to be studied in a large, scientifically rigorous study in patients with long COVID. Estimates of long COVID prevalence range from 5 to 50% of people who have had a COVID-19 infection. It affects people who have had both mild and severe COVID-19, including children, and can be severe enough to keep people out of work.

☆ Pfizer, facing lawsuit, says minority fellowship program serves public interest
▼ + stars: | 2022-10-26 | by ( Jonathan Stempel | ) www.reuters.com time to read: +2 min

NEW YORK, Oct 26 (Reuters) - Pfizer Inc (PFE.N) said its fellowship program for minorities serves the public interest, as the drugmaker defends against a lawsuit by a group of medical professionals that claims the program illegally excludes whites and Asian-Americans. Fellows receive two years of full-time jobs, fully-funded master's degrees, and employment at New York-based Pfizer after completing the program. The fellowship program "does what Congress has encouraged and controlling law allows," Pfizer said. Among the precedents at risk is a 2003 Supreme Court decision where Justice Sandra Day O'Connor said race could be used as one factor among many to achieve diversity. The case is Do No Harm v. Pfizer Inc, U.S. District Court, Southern District of New York, No.

☆ Final Trades: MKTX, HAL, PFE & BA
▼ + stars: | 2022-10-21 | by ( Melissa Lee | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: MKTX, HAL, PFE & BAThe final trades of the week. With CNBC's Frank Holland and the Fast Money traders, Tim Seymour, Steve Grasso, Guy Adami and Julie Biel.

☆ Beware of fad stocks. Truly owner, Snap & Zoom have plunged
▼ + stars: | 2022-10-20 | by ( Paul R. La Monica | ) edition.cnn.com time to read: +4 min

The Sam Adams brewer, which also owns the hard seltzer brand Truly, is struggling as the popularity of alcoholic seltzer appears to be fading fast. “The continuing decline of the hard seltzer segment … is deeper than previously expected,” said Boston Beer founder and chairman Jim Koch on the company’s earnings call in July. Sam Adams owner Boston Beer made a big bet on Truly Hard Seltzer. Sales have slowed, the company is still losing money, its founders have left, and the stock has plunged nearly 80% this year. E-signature software company DocuSign (DOCU) and virtual health company Teladoc (TDOC) have also plunged this year after getting huge boosts from Covid in 2020.

☆ Moderna says Omicron booster response stays high through 3 months
▼ + stars: | 2022-10-19 | by ( ) www.reuters.com time to read: +1 min

Oct 19 (Reuters) - Moderna Inc (MRNA.O) said on Wednesday its COVID-19 vaccine booster targeting the BA.1 subvariant of Omicron generated a strong immune response against that variant, with antibody levels staying high for at least three months. Omicron-tailored shots by Pfizer Inc (PFE.N) and Moderna are already authorized by regulators in several countries. The United States has given the go-ahead for booster vaccines that target the currently circulating BA.4 and BA.5 subvariants of Omicron. "Clinical trial data now indicates that the superior immune response produced by our bivalent booster has durability for at least three months," Moderna Chief Executive Officer Stephane Bancel said in a statement. Moderna said it expects data from human trials of its BA.4/BA.5 targeted vaccine later this year.

☆ Addiction drug shows promise lifting long COVID brain fog, fatigue
▼ + stars: | 2022-10-18 | by ( Julie Steenhuysen | Nancy Lapid | ) www.reuters.com time to read: +6 min

Lauren Nichols, who has long COVID, takes a break and rests in a lounge bed in the office in her home in Andover, Massachusetts, U.S., August 3, 2022. Register now for FREE unlimited access to Reuters.com RegisterResearchers chasing long COVID cures are eager to learn whether the drug can offer similar benefits to millions suffering from pain, fatigue and brain fog months after a coronavirus infection. Younger, author of a scientific review of the drug as a novel anti-inflammatory, in September submitted a grant application to study LDN for long COVID. It worked so well that he ran a pilot study among 38 long COVID patients. He studied LDN in 18 long COVID patients, with 11 showing improvements, and said he believes larger, formal trials could determine whether LDN offers a true benefit.

Oct 13 (Reuters) - Pfizer (PFE.N) and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants of Omicron, generated a strong immune response and was well-tolerated in testing on humans. With the results, which the companies described as consistent with preclinical data, the partners are following up with human trial data that had previously been missing from their successful filings for regulatory approval. Register now for FREE unlimited access to Reuters.com RegisterThey did not disclose the levels of antibodies generated in the preliminary analysis of the study. Healthcare regulators for the European Union and the United States had already approved the upgraded shot last month, even though trial data from testing on humans had at the time not been available. “While we expect more mature immune response data from the clinical trial of our Omicron BA.4/BA.5-adapted bivalent vaccine in the coming weeks, we are pleased to see encouraging responses just one week after vaccination in younger and older adults," said Pfizer Chief Executive Albert Bourla.

☆ RSV vaccine race heats up with highly effective GSK shot
▼ + stars: | 2022-10-13 | by ( Natalie Grover | ) www.reuters.com time to read: +3 min

LONDON, Oct 13 (Reuters) - Data unveiled on Thursday showed GSK's (GSK.L) respiratory syncytial virus (RSV) vaccine was 82.6% effective in a keenly watched late-stage study involving older adults. The company is a key player in the race to develop a safe and effective RSV vaccine, which, if approved, is expected to generate billions in sales for its maker. If approved, Jefferies analysts have forecast $2.5 billion in global RSV vaccine peak sales in older adults for GSK. U.S. drugmaker Pfizer (PFE.N) in August disclosed positive Phase III data on its rival RSV vaccine in older adults. In trial participants with pre-existing conditions, the GSK vaccine was shown to be 94.6% effective, while in adults aged 70 to 79 it was 93.8% effective, the company said.

☆ What Cramer is watching Wednesday — more hot inflation, PepsiCo strong, drug stocks mixed
▼ + stars: | 2022-10-12 | by ( Jim Cramer | ) www.cnbc.com time to read: +4 min

Raymond James lowers price target on Club holding Procter & Gamble (PG) to $155 per share from $175; keeps outperform (buy) rating). Stanley Black & Decker (SWK) downgraded to equal weight from overweight (hold from buy) at Morgan Stanley. Piper Sandler cuts Yeti (YETI) price target to $48 per share from $76 but keeps overweight (buy) rating. Deutsche Bank lowers price targets on all asset gatherers: BlackRock (BLK), Blackstone (BX) and KKR (KKR). As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ U.S. authorizes updated COVID booster shots for children as young as 5
▼ + stars: | 2022-10-12 | by ( ) www.reuters.com time to read: +2 min

Oct 12 (Reuters) - U.S. health regulators authorized the use of Omicron-tailored COVID-19 booster shots from Moderna Inc (MRNA.O) and Pfizer Inc (PFE.N) in children as young as 5, a move that will expand the government's fall vaccination campaign. The U.S. Food and Drug Administration on Wednesday green-lighted Moderna's bivalent vaccine for those aged six and above, while Pfizer's updated shot was authorized in children aged five and above. The U.S. Centers for Disease Control and Prevention also backed the FDA's authorization, clearing the way for the shots to be administered in children. Overall, COVID-19 vaccination rates in the United States have stayed low among kids, with nearly 40% of children aged 5-11 vaccinated with one dose of a vaccine so far. Around 11.5 million people received the updated shots over the first five weeks of the rollout last month, which represents just 5.4% of the people aged 12 or older who are eligible to receive them.

☆ Pfizer exec denies CEO negotiated EU COVID vaccine contract via text message
▼ + stars: | 2022-10-10 | by ( ) www.reuters.com time to read: +1 min

FRANKFURT, Oct 10 (Reuters) - A Pfizer (PFE.N) executive with a lead role in negotiating a COVID-19 vaccine bulk supply agreement with the European Commission "categorically" ruled out that the U.S. drugmaker's chief executive agreed the contract via mobile phone text messages. She added that such talks involve far too many people on both sides and take far too long to be conducted via mobile phone texts. The Commission said in June this year that it no longer had the texts, which later drew criticism from the European Union's ombudswoman. The contract signed last year was the biggest ever sealed for COVID-19 vaccines, with the EU committing to buy 900 million Pfizer-BioNTech (22UAy.DE) shots, with an option to buy another 900 million. Register now for FREE unlimited access to Reuters.com RegisterReporting by Ludwig Burger; Editing by Jan Harvey and Susan FentonOur Standards: The Thomson Reuters Trust Principles.

Mackay, 60, will be retiring next year after serving as GSK's finance chief for nearly four years, following an eight-year stint as group finance director at the bank HSBC. Register now for FREE unlimited access to Reuters.com RegisterBrown, also 60, will join GSK in April and take up the job in May. She also served in several finance roles at AstraZeneca (AZN.L), which last year also appointed a female CFO, Aradhana Sarin. With Emma Walmsley as GSK's chief executive officer, Brown's appointment also creates a rare, all-female top management at a blue-chip (.FTSE) British company and a global pharma major. Brown will receive an annual base salary of more than 900,000 pounds at GSK, the company said.

☆ Pfizer/BioNTech seek FDA nod for new COVID boosters for children
▼ + stars: | 2022-09-26 | by ( ) www.reuters.com time to read: +1 min

A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier/File PhotoSept 26 (Reuters) - Pfizer Inc (PFE.N) and its German partner BioNTech on Monday sought the U.S. Food and Drug Administration's authorization for an Omicron-tailored COVID-19 vaccine booster for children aged 5 through 11 years. The rollout of bivalent booster doses for older age groups has been off to a slow start in the United States compared to the rollout of the first boosters last year, with 4.4 million doses administered so far. read moreEarlier in the month, the U.S. Centers for Disease Control and Prevention said it expects COVID-19 vaccine boosters targeting circulating variants of the virus to be available for children aged 5-11 years by mid-October. Register now for FREE unlimited access to Reuters.com RegisterReporting by Leroy Leo and Khushi Mandowara in Bengaluru; Editing by Savio D'SouzaOur Standards: The Thomson Reuters Trust Principles.

☆ Pfizer CEO tests positive for COVID for a second time
▼ + stars: | 2022-09-24 | by ( ) www.reuters.com time to read: +2 min

Register now for FREE unlimited access to Reuters.com RegisterAlbert Bourla, CEO of Pfizer attends a discussion at the World Economic Forum (WEF) in Davos, Switzerland May 25, 2022. REUTERS/Arnd WiegmannSept 24 (Reuters) - Pfizer Inc (PFE.N) Chief Executive Officer Albert Bourla said on Saturday he had tested positive for COVID-19. Bourla has received four doses of the COVID vaccine developed by Pfizer and its German partner BioNTech (22UAy.DE). A federal health agency said this week that over 25 million doses of the so-called bivalent shots had been sent out. read moreRegister now for FREE unlimited access to Reuters.com RegisterReporting by Mrinmay Dey in Bengaluru; Editing by Daniel WallisOur Standards: The Thomson Reuters Trust Principles.

☆ Moderna seeks FDA nod for Omicron-targeted COVID shot for adolescents, younger kids
▼ + stars: | 2022-09-23 | by ( ) www.reuters.com time to read: +1 min

Register now for FREE unlimited access to Reuters.com RegisterA vial labelled "Moderna COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. The company is seeking emergency use authorization of its updated vaccine in two age groups - adolescents aged 12 to 17 years and children aged six to 11. Moderna's mRNA-1273.222, a bivalent booster shot, contains the dominant BA.4/BA.5 variants along with the original coronavirus strain. read moreThe U.S. government has ordered more than 170 million updated vaccine booster shots for this fall, and said on Tuesday it had sent out over 25 million doses to be distributed. Register now for FREE unlimited access to Reuters.com RegisterReporting by Mrinalika Roy in Bengaluru; Editing by Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.

☆ U.S. rollout of new COVID boosters off to slow start
▼ + stars: | 2022-09-23 | by ( ) www.reuters.com time to read: +3 min

A nurse fills up syringes with the coronavirus disease (COVID-19) vaccines for residents who are over 50 years old and immunocompromised and are eligible to receive their second booster shots in Waterford, Michigan, U.S., April 8, 2022. The government said earlier this week it has shipped 25 million of the Omicron-tailored shots, mostly from Pfizer (PFE.N)/BioNTech (22UAy.DE). Last year, when the United States initially authorized COVID boosters just for older and immunocompromised people, nearly 10 million received their third shot in the first three weeks. The updated shots target the widely circulating BA.4 and BA.5 Omicron subvariants as well as the original version of the coronavirus included in all previous COVID vaccines. Moderna had been producing new boosters aimed at the older BA.1 Omicron subvariant when the FDA asked them to change course to address the currently dominant variants for the U.S. market.

☆ U.S. cutting global donations of Pfizer COVID shots as demand slows
▼ + stars: | 2022-09-22 | by ( Michael Erman | ) www.reuters.com time to read: +2 min

REUTERS/Rodrigo GarridoNEW YORK, Sept 22 (Reuters) - The United States is significantly cutting back the number of Pfizer (PFE.N)/BioNTech (22UAy.DE) COVID-19 vaccine doses it will buy for donation to poorer nations this year, Pfizer said on Thursday, citing diminished demand for the shots in those countries. The United States will have an option to buy up to an additional 400 million shots for the program after this year. Pfizer said it had already delivered 400 million vaccine doses in 79 countries under the U.S. government contract. The vaccine doses were donated through the COVAX program, run by the World Health Organization and GAVI global vaccine alliance, which was intended to deliver COVID-19 shots to the world's poorer countries. COVAX has been negotiating since june with vaccine manufacturers to cut or slow deliveries of 400 million to 600 million vaccine doses from its own contracts.

☆ Pfizer to supply up to 6 mln COVID pill courses for lower income countries
▼ + stars: | 2022-09-22 | by ( ) www.reuters.com time to read: +1 min

Register now for FREE unlimited access to Reuters.com RegisterA 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. Pfizer said the supply agreement is part of its strategy to facilitate equitable access to oral COVID treatments. Register now for FREE unlimited access to Reuters.com RegisterThe company has made a deal with several generic drugmakers to produce its treatment at a lower price for developing countries. "This agreement with Global Fund is a critical step that will boost equitable access for high-risk patients in low-and-middle income countries," Chief Executive Officer Albert Bourla said in a statement. Register now for FREE unlimited access to Reuters.com RegisterReporting by Mrinalika Roy in Bengaluru; Editing by Vinay DwivediOur Standards: The Thomson Reuters Trust Principles.

☆ Two-Minute Drill: GOOGL, MSFT & PFE
▼ + stars: | 2022-09-22 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTwo-Minute Drill: GOOGL, MSFT & PFEAadil Zaman, Wall Street Alliance Group, joins 'Closing Bell: Overtime' to discuss three stocks: Alphabet, Microsoft and Pfizer.

☆ U.S. CDC expects Omicron COVID boosters for kids by mid-October
▼ + stars: | 2022-09-21 | by ( ) www.reuters.com time to read: +1 min

REUTERS/Hannah BeierSept 21 (Reuters) - The U.S. Centers for Disease Control and Prevention expects COVID-19 vaccine boosters targeting circulating variants of the virus to be available for children aged 5-11 years by mid-October. Register now for FREE unlimited access to Reuters.com RegisterThe CDC said it expects Pfizer-BioNTech's (PFE.N), bivalent vaccine to be available for children aged 5-11 years, and Moderna's (MRNA.O) vaccine for those aged 6-17 years, pending FDA authorization. The Pfizer vaccine is already authorized as a booster dose for children over 12 years of age, while Moderna's bivalent vaccine is authorized for adults. The CDC expects pre-orders for the Pfizer shot to begin for the age group next week. The Moderna vaccine will have the same formulation for children and adults and will not require a separate pre-order period, the CDC said.

☆ Haleon rejects Zantac indemnification requests from GSK, Pfizer
▼ + stars: | 2022-09-20 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Brendan McDermidLONDON, Sept 20 (Reuters) - Haleon (HLN.L) on Tuesday said it had notified GSK (GSK.L) and Pfizer (PFE.N) that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac. More than 2,000 legal cases related to Zantac have been filed in the United States over allegations that the compound contains a probable carcinogen. Zantac, originally marketed by a forerunner of GSK, has been sold by several companies at different times, including Pfizer, Boehringer Ingelheim and Sanofi (SASY.PA) as well as a plethora of generic drugmakers. Haleon - alongside GSK, Sanofi and Pfizer - saw billions wiped off their market value last month as uncertainty around the outcome of the impending litigation triggered investor concern, although some of those losses have been since pared back. However, in August, Haleon clarified that it never marketed Zantac in any form in the U.S., either as Haleon or as GSK consumer healthcare.

Search resuls for: "PFE"

25 mentions found